Dishman Carbogen Amcis Ltd Stock Price Today (NSE: DCAL)
Fundamental Score
Dishman Carbogen Amcis Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dishman Carbogen Amcis Ltd share price today is ₹186.94, up +0.89% on NSE/BSE as of 31 July 2026. Dishman Carbogen Amcis Ltd (DCAL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.03K (Cr). The 52-week high for DCAL share price is ₹321.95 and the 52-week low is ₹128.50. At a P/E ratio of 30.53x, DCAL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 1.58% and a debt-to-equity ratio of 0.46.
Dishman Carbogen Amcis Ltd Share Price Chart — NSE/BSE Historical Performance
Dishman Carbogen Amcis Ltd share price chart: 6.23% return over the past month. 52-week high ₹321.95, 52-week low ₹128.50.
Dishman Carbogen Amcis Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹188.49 | ₹188.49 | ₹184.04 | ₹186.94 | 70.76K (Cr) | |
| ₹186.67 | ₹189.60 | ₹184.66 | ₹185.30 | 1.50L (Cr) | |
| ₹183.90 | ₹188.99 | ₹182.18 | ₹187.99 | 2.39L (Cr) | |
| ₹186.89 | ₹187.48 | ₹181.00 | ₹182.07 | 81.22K (Cr) | |
| ₹183.90 | ₹188.84 | ₹183.90 | ₹186.11 | 1.90L (Cr) | |
| ₹178.19 | ₹184.60 | ₹176.10 | ₹183.58 | 1.37L (Cr) | |
| ₹186.90 | ₹186.90 | ₹178.47 | ₹179.24 | 2.49L (Cr) | |
| ₹192.00 | ₹193.00 | ₹187.34 | ₹190.19 | 1.36L (Cr) | |
| ₹190.00 | ₹192.82 | ₹189.57 | ₹190.83 | 90.19K (Cr) | |
| ₹193.32 | ₹193.60 | ₹189.11 | ₹191.46 | 2.45L (Cr) |
Dishman Carbogen Amcis Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹176.00 | ₹204.50 | ₹175.00 | ₹186.94 | +6.22% | |
| ₹195.65 | ₹202.00 | ₹167.25 | ₹175.37 | -10.37% | |
| ₹184.80 | ₹224.40 | ₹173.80 | ₹194.70 | +5.36% | |
| ₹136.73 | ₹192.20 | ₹132.20 | ₹183.18 | +33.97% | |
| ₹169.33 | ₹177.58 | ₹128.50 | ₹129.97 | -23.24% | |
| ₹214.78 | ₹233.85 | ₹173.50 | ₹175.06 | -18.49% | |
| ₹248.80 | ₹267.00 | ₹200.35 | ₹218.47 | -12.19% | |
| ₹240.65 | ₹274.30 | ₹211.55 | ₹247.59 | +2.88% | |
| ₹292.00 | ₹302.90 | ₹228.00 | ₹239.20 | -18.08% | |
| ₹276.15 | ₹306.00 | ₹272.50 | ₹291.80 | +5.67% | |
| ₹263.70 | ₹321.95 | ₹260.00 | ₹275.60 | +4.51% | |
| ₹248.00 | ₹282.70 | ₹234.00 | ₹264.60 | +6.69% |
AI Research Briefing
Powered by Gemini · 2026-04-08
DCAL is a debt-laden small-cap with negative profitability metrics, making it a risky turnaround bet despite sector tailwinds.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Dishman Carbogen Amcis (DCAL) shares are volatile. The stock rose above its 15-day moving average on April 7, 2026. However, it also hit a new 52-week low recently. The company has secured debenture trustee consent for a financial covenant waiver on Crore NCDs. Vinay Goenka stepped down as Executive Chair on April 1, 2026.
CORE STORY (THE REAL GAME)
DCAL is a small-cap CRAMS player attempting a turnaround amidst sector tailwinds. The market is weighing its ability to improve profitability and manage debt.
- Recent volatility with a new 52-week low
- Securing NCD waivers offers short-term relief
- Sector growth provides a potential tailwind
- Significant order wins in CRAMS
- Successful debt restructuring
- Improved quarterly earnings with margin expansion
- Small-cap: liquidity risk
- Negative ROE, ROCE, and FCF
- High debt/equity ratio
FII decreased holdings by 1.87% [cite: Brief].
India's pharma exports are rising, but US tariff policies pose a risk.
No major news found after live search.
No: Free Cash Flow 5Y: ₹-69.39 Cr [cite: Brief].
DCAL aims for ₹500 crore revenue from India operations in 12-18 months and a 25-26% consolidated EBITDA margin within two years. Execution is key.
Primary Thesis Risk
Inability to manage debt and improve profitability will lead to collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dishman Carbogen Amcis Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dishman Carbogen Amcis Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DCAL across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (15.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (18.85%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (20.89% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.89% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (59.32%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.58%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-59.43%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (1.62x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 9.08%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dishman Carbogen Amcis Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Dishman Carbogen Amcis Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
43.6/100 | ₹186.94₹187 | ₹3026.08₹3026.08 | 30.53Average 30.5 Average | 1.58%Poor 1.58% Poor | 3.15%Poor 3.15% Poor | 0.46Excellent 0.5 Excellent | 20.89%Excellent 20.89% Excellent | 8.93%Good 8.93% Good | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Dishman Carbogen Amcis Ltd PE Ratio History
Historical price-to-earnings ratio for DCAL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.21 | ₹247.59 | 1179x |
| FY 2022 | ₹1.15 | ₹94.90 | 82.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dishman Carbogen Amcis Ltd Quarterly Performance
Latest quarterly metrics for DCAL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
18.85%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-59.43%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.93%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.89%
Compounded annual net profit growth over 5 years
Dishman Carbogen Amcis Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DCAL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dishman Carbogen Amcis Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Dishman Carbogen Amcis Ltd (DCAL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Dishman Carbogen Amcis Ltd
About DCAL (Dishman Carbogen Amcis Ltd)
D vitamins; and specialty chemicals, as well as provides services for early and late-stage contract research and manufacturing, and high-potency APIs. Dishman Carbogen Amcis Ltd i...s a globally recognized pharmaceutical company specializing in contract development and manufacturing organization (CDMO) services. With a strong emphasis on innovation and quality, DCAL provides comprehensive solutions to pharmaceutical and biotechnology companies from early-stage research to commercial manufacturing. The company's state-of-the-art facilities and experienced team of scientists and engineers offer a wide range of services including custom synthesis, process development, scale-up, analytical testing, and formulation development. DCAL is committed to meeting the evolving needs of its clients by delivering high-quality products and services in a timely and cost-effective manner. DCAL operates with a focus on advanced technologies and complex chemistries, enabling the development and manufacturing of specialized pharmaceutical products. The company excels in handling challenging molecules, including highly potent APIs (HPAPIs) and controlled substances, while maintaining the highest standards of safety and regulatory compliance. DCAL's expertise extends to various therapeutic areas, including oncology, neurology, and infectious diseases, and the company is dedicated to supporting its clients in bringing innovative medicines to market. Through its commitment to excellence, DCAL has established itself as a trusted partner for pharmaceutical companies worldwide. With a global footprint and a customer-centric approach, Dishman Carbogen Amcis Ltd strives to build long-lasting partnerships with its clients. The company's integrated services and collaborative approach ensure seamless project execution and efficient delivery of results. DCAL's commitment to sustainability and environmental responsibility further underscores its dedication to ethical business practices. By combining cutting-edge technology, scientific expertise, and a strong commitment to customer satisfaction, Dishman Carbogen Amcis Ltd continues to drive innovation and growth in the pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
DCAL Share Price: Frequently Asked Questions
What is the current share price of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd (DCAL) trades at ₹186.94 on NSE and BSE. Market cap ₹3.03K (Cr). Educational data only.
What is the P/E ratio of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd has a P/E of 30.53x vs industry average 34.89x.
What is the Bull Run score for Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd has a Bull Run score of 43.6/100 based on 25+ financial parameters.
Does Dishman Carbogen Amcis Ltd pay dividends?
Dishman Carbogen Amcis Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd has ROE of 1.58%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd has debt-to-equity of 0.46.
Is Dishman Carbogen Amcis Ltd a good investment?
Bull Run gives Dishman Carbogen Amcis Ltd a score of 43.6/100. This is not investment advice — consult a SEBI-registered advisor.